Follow this innovation
[ via 
] [?]
GP VI: A Novel Target for Inflammatory Arthritis
Brigham and Women's Hospital
posted on 05/12/2011
Technology: In addition to their role in thrombosis and wound repair, platelets have a role in inflammation. Using pharmacologic and genetic approaches, the inventors have identified the collagen receptor glycoprotein VI as a key trigger of platelet microparticle generation in arthritis. These platelet microparticles are pro-inflammatory and elicit a cytokine response from synovial fibroblasts via IL-1 in the synovial fluid of patients with rheumatoid arthritis and other forms of inflammatory arthritis. Moreover, depletion of these platelets attenuated inflammatory arthritis in murine models. The collagen receptor glycoprotein VI is a potential new target for inflammatory arthritis Applications: - Therapeutic: A method of treatment of rheumatoid and other forms of inflammatory arthritis targeting GP VI - Diagnostic: A biomarker to assess effectiveness of drugs targeted to GP VI Advantages: - Novel therapeutic target - Potential companion diagnostic - Potential synergies with other targets of inflammation Publication: Science 29 January 2010: Vol. 327. no. 5965, pp. 580 - 583 Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production - Eric Boilard & al.
File Number: 20161
Other Information: *Investigator(s)*
Richard Eric; Farndale David ; Boilard Jerry ; Lee Ware
*Contact*
Ulysses Sallum, 617-954-9535
This innovation currently is not available for online licensing. Please contact Mary Auge at Brigham and Women's Hospital for more information.
request more info
ProfileFind more innovations
